Table 3.
Univariate and multivariate analyses in patients treated with allo-HSCT
| Variables | EFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Univariate analyses | ||||
| MiR-363 (high vs. low) | 1.182 (0.643–2.175) | 0.590 | 1.424 (0.775–2.619) | 0.255 |
| WBC (≥ 20 vs. < 20 × 109/L) | 1.089 (0.594–1.999) | 0.782 | 0.826 (0.450–1.516) | 0.537 |
| FLT3–ITD (positive vs. negative) | 1.876 (0.914–3.851) | 0.086 | 1.973 (0.953–4.084) | 0.067 |
| NPM1 (mutated vs. wild) | 1.007 (0.515–1.970) | 0.983 | 1.023 (0.523–1.998) | 0.948 |
| DNMT3A (mutated vs. wild) | 1.285 (0.655–2.520) | 0.466 | 1.387 (0.704–2.731) | 0.344 |
| RUNX1 (mutated vs. wild) | 1.145 (0.449–2.290) | 0.777 | 1.579 (0.613–4.067) | 0.344 |
| TP53 (mutated vs. wild) | 2.034 (0.718–5.760) | 0.181 | 4.334 (1.453–12.925) | 0.009 |
| TET2 (mutated vs. wild) | 0.526 (0.127–2.186) | 0.377 | 0.670 (0.162–2.776) | 0.581 |
| MLL–PTD (mutated vs. wild) | 5.775 (1.664–20.042) | 0.006 | 2.728 (0.832–8.944) | 0.098 |
| IDH1/IDH2 (mutated vs. wild) | 0.587 (0.271–1.273) | 0.177 | 0.633 (0.293–1.368) | 0.245 |
| NRAS/KRAS (mutated vs. wild) | 0.796 (0.245–2.586) | 0.705 | 0.488 (0.150–1.587) | 0.233 |
| Multivariate analyses | ||||
| MLL–PTD (mutated vs. wild) | 5.180 (1.449–18.511) | 0.011 | 3.136 (0.943–10.429) | 0.062 |
| FLT3–ITD (positive vs. negative) | 1.837 (0.868–3.888) | 0.112 | 2.301 (1.090–4.860) | 0.029 |
| TP53 (mutated vs. wild) | 2.493 (0.860–7.226) | 0.092 | 5.848 (1.885–18.142) | 0.002 |
EFS event-free survival, OS overall survival, WBC white blood cell